Tylenol vs Synaptive Medical

Side-by-side comparison of AI visibility scores, market position, and capabilities

Tylenol leads in AI visibility (76 vs 54)
Tylenol logo

Tylenol

LeaderHealthcare

General

Global #1 OTC acetaminophen brand owned by Kenvue (NYSE: KVUE, J&J 2023 spinoff at $41B); Kimberly-Clark $48.7B Kenvue acquisition pending close H2 2026 competing with Advil and store brand for OTC pain relief market.

AI VisibilityBeta
Overall Score
B76
Category Rank
#72 of 596
AI Consensus
81%
Trend
stable
Per Platform
ChatGPT
82
Perplexity
76
Gemini
76

About

Tylenol is a global over-the-counter acetaminophen (paracetamol) pain relief and fever reducer brand — owned by Kenvue (NYSE: KVUE), the consumer health company spun off from Johnson & Johnson in May 2023 at a $41 billion IPO valuation, and subject to a pending $48.7 billion acquisition by Kimberly-Clark announced in November 2025 (expected to close second half 2026) — providing consumers with the world's most widely used analgesic through product lines including Tylenol Extra Strength, Tylenol PM, Tylenol Rapid Release Gels, Tylenol Children's, and Tylenol Arthritis Pain for adults and pediatric pain and fever management. Generating approximately $2 billion in annual retail sales as one of Kenvue's flagship brands alongside Neutrogena, Band-Aid, Listerine, and Zyrtec, Tylenol is the #1 recommended pain reliever by doctors and pharmacists in the United States. Originally marketed by McNeil Laboratories (acquired by J&J in 1959), the brand was approved for OTC sale in 1960.

Full profile
Synaptive Medical logo

Synaptive Medical

ChallengerHealthcare

Neurosurgical Robotics & Imaging

Synaptive Medical raised $260M total; secured new strategic investment in Jul 2025 to accelerate growth; BrightMatter robotic imaging suite enhances neurosurgical precision with 3D tractography navigation.

AI VisibilityBeta
Overall Score
C54
Category Rank
#203 of 596
AI Consensus
78%
Trend
stable
Per Platform
ChatGPT
59
Perplexity
50
Gemini
55

About

Synaptive Medical is a Toronto-based medical device company founded in 2012 that develops integrated surgical robotics, imaging, and navigation solutions for neurosurgery. Its flagship product line — the BrightMatter suite — includes BrightMatter Prime (pre-operative planning with high-fidelity imaging), BrightMatter Guide (FDA-cleared 3D neuronavigation with tractography), and BrightMatter Servo (robotic microscope positioning with hands-free alignment and real-time 3D tractography visualization in the OR).

Full profile

AI Visibility Head-to-Head

76
Overall Score
54
#72
Category Rank
#203
81
AI Consensus
78
stable
Trend
stable
82
ChatGPT
59
76
Perplexity
50
76
Gemini
55
82
Claude
53
77
Grok
51

Key Details

Category
General
Neurosurgical Robotics & Imaging
Tier
Leader
Challenger
Entity Type
product
brand

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.